The International Foundation of Employee Benefit Plans survey shows that roughly 30% of employers who currently cover the medication for weight loss say theyre considering restricting that coverage to control costs
EXPERIENCE: One of the leading practitioners in Australia who has treated over 2,500 patients
In summary, tirzepatide is the first dual receptor agonist that was recently approved for the treatment of T2D by the FDA
Several technical advancements contribute to more natural body contouring outcomes: Progressive tension sutures: Reduce dead space and the need for drains while allowing more precise tissue repositioning
Novo Nordisk has also highlighted that in many cases, the conditions claimed in lawsuits were pre-existing or not definitively linked to their product
Programs that include coaching, community support, and habit-building tools can help people build routines that support their health during and after treatment